Valneva is developing a Lyme disease vaccine candidate with potential market opportunity as Lyme disease cases continue to rise. Key risks include regulatory approval uncertainty, competition from other vaccine developers, and clinical trial outcomes.

Valneva (VALN) is developing a Lyme disease vaccine currently in stage 3 trials with 70% efficacy, positioned to capitalize on rising tick populations and a 40% increase in Lyme disease cases this year. Key risks include vaccine approval uncertainty, competition, and efficacy rate may be insufficient for market adoption.